Frontlight ResearchEarly access
Active, not recruitingNo phase
Assessment of DOT Spectacles in Chinese Children Extension
Key facts
- Who runs it
- SightGlass Vision, Inc.
- Where
- China5 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 175 people, planned
- Started
- 1 Aug 2025
- Expected to end
- 30 Jun 2027
- Type of study
- Interventional, 2 groups
- Treatments tested
- Novel spectacle lens design
- Record updated
- 17 November 2026
Who can take part
- Age
- 8 years to 16 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Previously a successfully completed participant in the CATHAY study (NCT05562622)
- Agree to wear the assigned spectacles constantly except for sleeping, swimming, or other activities in which spectacle wear would be dangerous or otherwise not possible (minimum of 10 hours per day)
- Willingness to participate in the trial for 12 months without contact lens wear or any other myopia management intervention
- The subject's parent(s) or legal guardian(s) must read, understand and sign the Statement of Informed Consent and receive a fully executed copy of the form
Who cannot take part
- Known allergy to proparacaine, tetracaine, or tropicamide or cyclopentolate
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a randomized, controlled, open-label, evaluator-blinded, multicenter, clinical trial of 12-months duration to evaluate the continued safety and efficacy of Diffusion Optics Technology (DOT) spectacle lenses in reducing the progression of juvenile myopia in children of Chinese origin.
The 2 groups in the trial
- SightGlass Vision Test Arm Groups I (formerly test group)Treatment being tested
Single vision, impact-resistant spectacle lenses
Treatment: Novel spectacle lens design
- SightGlass Vision Test Arm Groups II (formerly control group)Treatment being tested
Single vision, impact-resistant spectacle lenses
Treatment: Novel spectacle lens design
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Clinical Assessment of DOT Spectacle Lenses in Chinese Children Extension
- Record updated
- 17 November 2026